GlassScriptPhysician profile
Muhammad S Haroon
NPI 1326048927
$371.84
in general payments reported to CMS, 2019-2025
14 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.04 · 2021: $37.71 · 2022: $37.86 · 2023: $110 · 2024: $42.02 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195 · Education: $88.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.74 |
| Education | $88.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $56.97 | 2021-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $47.88 | 2023 | Epkinly, Imbruvica |
| Daiichi Sankyo INC. | $32.12 | 2023-2025 | Enhertu |
| Pfizer INC. | $26.28 | 2020-2022 | |
| Servier Pharmaceuticals LLC | $24.62 | 2025 | |
| Abbvie INC. | $23.44 | 2024 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Cti Biopharma Corp. | $16.94 | 2023 | Vonjo |
| Takeda Pharmaceuticals U.S.A., INC. | $16.79 | 2023 | Iclusig |
| Astellas Pharma US INC | $14.37 | 2023 | Xospata |
| Glaxosmithkline, LLC. | $12.02 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Haroon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.